Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells

Drugs under Experimental and Clinical Research

Volumn 31, Issue 5-6, 2005, Pages 215-219

  Matsui, T ^a   Yamagishi, S ^a   Nakamura, K ^a   Kikuchi, S ^b   Inoue, H ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZELNIDIPINE; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; MESSENGER RNA; NITRENDIPINE; PIGMENT EPITHELIUM DERIVED FACTOR; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PROTEIN INTERACTION; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; AZETIDINECARBOXYLIC ACID; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; DIHYDROPYRIDINES; ENDOTHELIAL CELLS; EYE PROTEINS; GENE EXPRESSION REGULATION; HUMANS; MICROCIRCULATION; NERVE GROWTH FACTORS; NITRENDIPINE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SERPINS;

EID: 30144438668     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tombran-Tink J., Chader C.G., Johnson L.V. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res., 53, 411, 1991.
2. Wu Y.Q., Notario V., Chader G.J., Becerra S.P. Identification of pigment epithelium-derived factor in the interphotoreceptor matrix of bovine eyes. Protein Expr. Purif., 6, 447, 1995.
3. Becerra S.P. Structure-function studies on PEDF. A noninhibitory serpin with neurotrophic activity. Adv. Exp. Med. Biol., 425, 223, 1997.
4. Dawson D.W., Volpert O.V., Gillis P., et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science, 285, 245, 1999.
5. Duh E.J., Yang H.S., Suzuma I., et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci., 43, 821, 2002.
6. Yamagishi S., Inagaki Y., Amano S., et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun., 296, 877, 2002.
7. Amano S., Yamagishi S., Inagaki Y., et al. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc. Res., 69, 45, 2005.
8. Wellington K., Scott L.J. Azelnidipine. Drugs, 63, 2613, 2003.
9. Yamagishi S., Inagaki Y., Nakamura K., Imaizumi T. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J. Cardiovasc. Pharmacol., 43, 724, 2004.
10. Yamagishi S., Matsui T., Nakamura K., Inoue H. Pigment epithelium-derived factor (PEDF) is a pericyte mitogen secreted from microvascular endothelial cells: A possible participation of angiotensin II-elicited PEDF down-regulation in diabetic retinopathy. Int. J. Tissue React., 2005 (in press).
11. Yamagishi S., Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp. Clin. Res., 30, 169, 2004.
12. Yamagishi S., Inagaki Y., Nakamura K., et al. Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J. Mol. Cell Cardiol., 37, 497, 2004.
13. Yamagishi S., Nakamura K., Ueda S., Kato S., Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell & Tissue Res., 320, 437, 2005.
14. Mark I.T., Weglicki W.B. Antioxidant activity of calcium channel blocking drugs. Methods Enzymol., 234, 620, 1994.
15. Yamagishi S., Matsui I., Inoue H. Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells. Drugs Exp. Clin. Res., 2005 (in press).
16. Yamagishi S., Imaizumi T. Diabetes vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des., 11, 2279, 2005.
17. Inagaki Y., Yamagishi S., Okamoto T., Takeuchi M., Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia, 46, 284, 2003
18. Spranger J., Osterhoff M., Reimann M., et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes, 50, 2641, 2001.
19. Boehm B.O., Lang G., Volpert O., et al. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia, 46, 394, 2003.
20. Kuramoto K., Ichikawa S., Hirai A., et al. Azelnidipine and amlodipine: A comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens. Res., 26, 201, 2003.